NICE turns down Tecentriq in bladder cancer but suggests Roche try again for some patients
admin 2nd August 2017 Uncategorised 0Roche and England’s drug cost watchdog NICE are again in an arm-wrestling contest, this time over the use of Roche’s cancer drug Tecentriq for metastatic urothelial cancer.
More: NICE turns down Tecentriq in bladder cancer but suggests Roche try again for some patients
Source: fierce